Epidemiological studies have suggested an inverse correlation between high density lipoprotein (HDL) cholesterol levels and the risk of cardiovascular disease. HDLs promote reverse cholesterol transport (RCT) and possess several putative atheroprotective functions, associated to the anti-inflammatory, anti-thrombotic and anti-oxidant properties as well as to the ability to support endothelial physiology.
Introduction
Epidemiological studies have suggested an inverse relationship between high density lipoprotein (HDL) cholesterol (HDL-C) levels and the risk of atherosclerotic cardiovascular disease [1] . The atheroprotective role of HDL is related to their key function in reverse cholesterol transport (RCT), as well as a number of additional potentially favorable properties including anti-inflammatory, antithrombotic, and antioxidant effects ( Figure 1 ) [2] . Accordingly, several efforts to develop drugs to increase HDL-C levels have been undertaken [3] . These approaches, including those aimed at increasing apolipoprotein A-I (apoA-I) levels, have shown some beneficial effects either in preclinical studies [4] [5] [6] or in patients with coronary heart disease (CHD) [7] [8] [9] [10] . However, recent clinical trials evaluating the effects of HDL-C-raising therapies have failed to demonstrate a benefit on cardiovascular outcomes [11] [12] [13] , with the exception of the recent REVEAL study on anacetrapib [14] . In addition, Mendelian randomization analyses have shown that single nucleotide polymorphisms that exclusively associate with higher HDL-C levels do not associate with a reduced risk of myocardial infarction [15] . These findings, together with the observation that the inverse relationship between HDL-C levels and cardiovascular risk is present only in healthy subjects or in patients without CHD, while it is significantly weakened in patients with cardiovascular disease [16, 17] , raised the question of whether HDL-C level is the right parameter to follow in clinic, and set the stage for testing the clinical relevance of changes in HDL function [18] [19] [20] . This possibility is supported by several observations: i) increased concentrations of lecithin-cholesterol acyltransferase (LCAT), which are associated with increased HDL-C levels, do not necessarily associate with atheroprotection and, conversely, LCAT deficiency, characterized by lower levels of HDL-C, does not associate with increased risk of atherosclerosis [21] . ii) HDL cholesterol efflux capacity is inversely associated with the incidence of cardiovascular events in a populationbased cohort free from cardiovascular disease, an association that persists even after adjustment for HDL-C levels or HDL particle concentrations [22] and predicts atherosclerotic burden better than HDL-C levels [22] [23] [24] [25] . iii) The use of apoA-I mimetic peptides may improve HDL activities without changing its mass [26] . A recent study reported that the administration of the apoA-I mimetic peptide D-4F reduced the HDL-inflammatory burden in patients at high CHD risk, suggesting that this approach might result in improved HDL functions [27] . iv) Very high HDL-C levels and very large HDL particles associate with no cardiovascular benefit or even an increased risk of coronary artery disease (CAD) [28] [29] [30] . A possible explanation for these findings is related to the presence of "dysfunctional" HDL, i.e. HDL particles that have lost their atheroprotective functions and may be even pro-atherogenic ( Figure 1 ). It is conceivable, therefore, that measuring HDL-C levels, although will capture the relative contribution of "protective HDL" not always will inform on their absolute levels or activity, and this might explain the observed disconnection of these measurements.
In this review we will discuss the biological effects of dysfunctional HDL and their possible relationship with atherosclerotic related diseases.
HDL STRUCTURE, COMPOSITION AND FUNCTIONS
HDL family includes both discoidal and spherical particles, heterogeneous in density, shape, size and electrophoretic mobility, which undergo continuous remodeling processes mediated by lipolytic enzymes and lipid transfer proteins. ApoA-I is the main apoprotein of HDL (70%) and plays relevant functions either as structural or functional protein [31] . ApoA-II is the second major apolipoprotein of HDL (15-20% of total proteins) and has the ability to displace apoA-I from HDL. Increased levels of apoA-II associated-HDL therefore dampen the function of apoA-I-containing HDL on reverse cholesterol transport, scavenger receptor class B type I (SR-BI) dependent hepatic cholesterol catabolism as well as the activity of enzymes involved in HDL metabolism [32] . However, HDL carry additional apoproteins (including apoE, apoCs, apoA-IV, apoA-V, apoJ, apoF, apoM, apoL1), enzymes involved in lipid metabolism (including LCAT and phospholipid transfer protein [PLTP]) as well as antioxidant enzymes, such as paraoxonase 1 (PON1), platelet-activating factor-acetyl hydrolase (PAF-AH) and glutathione selenoperoxidase (GSPx), acute phase response proteins (including serum amyloid A [SAA]) and complement components [31] .
Based on surface charge and shape, HDL may be distinguished in pre-ß-migrating and migrating particles. Pre-ß particles are mainly nascent discoidal lipoproteins containing apoA-I, phospholipids and free cholesterol and a very small core of neutral lipids, while -migrating particles are "mature" quasi-spherical lipoproteins containing a hydrophobic core of cholesteryl esters (CE) and triglycerides (TG). Based on their density, HDL can also be classified as the large lipid-rich HDL2 and the small dense HDL3 [31] . HDL2 and HDL3 can be further subfractionated into 5 distinct subpopulations by native gradient gel electrophoresis based on their size, resulting in HDL2a and 2b and HDL3a, 3b and 3c [31] . Finally, HDL can be separated according to their apoprotein content into particles containing only apoA-I (LpA-I) or both apoA-I and apoA-II (LpA-I:A-II) [31] (Figure 2 ). Due to the different methodologies used to measure HDL subclasses, it is difficult to find relations among them. For this reason, a classification of HDL based on density and size has been proposed, leading to the identification of five HDL subclasses (very large, large, medium, small and very small HDL) which should help to identify a relationship between these subclasses and cardiovascular risk [33] ( Figure   2 ). HDL particles differ also for their proteome and lipidome, with some subfractions carrying specific and distinct components not present in others. For example, HDL3c particles carry predominantly some proteins (including apoJ, PON1, PLTP, PAF-AH) [34] associated with its high antioxidant capacity. Instead, apoE and apoCs are preferentially carried by HDL2 [35] ; these apoE-rich, large HDL particles are involved in the reverse cholesterol transport process through the interaction with scavenger receptor type B class I (SR-BI) and ATP-binding cassette transporter G1 (ABCG1) [36] . Again, sphingosine-1-phosphate (S1P), a minor bioactive lipid, is associated mainly with HDL3 particles [37] . HDL possess several potential atheroprotective functions ( Figure 1 ). The most studied property of HDL is its role in RCT, the process by which excess cholesterol is believed to be transported from the peripheral tissues to the liver for excretion [38] [39] [40] . This process involves two main steps ( Figure 3 ). During the first step, lipid-free or lipid-poor apoA-I (referred to as pre-ß HDL) accepts cholesterol from membranes of lipid-loaded cells of the arterial wall through the interaction with ATP-cassette binding transporter A1 (ABCA1). Circulating LCAT then esterifies free cholesterol and generates more mature HDL particles (-particles) containing a lipid core composed by highly hydrophobic lipids (mainly cholesteryl esters, CE) and that can further accept cholesterol from cells following the interaction with ABCG1, ABCG4 [39, 41, 42] or SR-BI [43] . RCT is then completed by a third step during which CE are delivered to the liver; this occurs by two different mechanisms: 1) directly, through the interaction of hepatic SR-BI and mature HDL particles, 2) indirectly, following the cholesteryl ester transfer protein (CETP)-mediated transfer of CE from HDL particles to VLDL and LDL and subsequent clearance by hepatic LDLR [40] .
HDL possess anti-inflammatory properties [44, 45] . Experimental evidence demonstrates that HDL inhibit the endothelial activation induced by inflammation: the expression of surface adhesion molecules and chemoattractant proteins is reduced [46] [47] [48] [49] [50] [51] [52] [53] , thus decreasing the recruitment of monocytes, dendritic cells and T lymphocytes at sites of inflammation [54] and controlling the immune response. HDL may also act on circulating leukocytes to limit inflammation, for example by inhibiting the activation of CD11b, a surface protein involved in monocytes adhesion [55] . In addition, HDL inhibit the inflammasome activation and its downstream inflammatory cytokines through several mechanisms, thus reducing inflammation [56] . Different HDL subfractions exhibit different anti-inflammatory properties, being small dense HDL3 more efficient than large HDL2 in inhibiting the expression of endothelial adhesion molecules [57] . HDL3, probably due to its unique proteome [34] , possess the highest ability to prevent LDL oxidation as well as the OxLDL-induced apoptosis of endothelial cells [58, 59] .
Small dense HDL3 remove oxidized lipids from lipoproteins and cellular membrane more efficiently that large HDL2, an effect probably related to a reduced content in sphingomyelin and free cholesterol [37] which increases the fluidity of the surface lipid monolayer and facilitates the incorporation of oxidized lipids [60] . Spherical HDL have a higher inhibitory effect compared with discoidal particles [61] . Both proteins and lipids associated with HDL contribute to its anti-inflammatory activity. Modifications of HDL, such as glycation or oxidation, impair the anti-inflammatory capacity of HDL and instead generate particles with pro-inflammatory activity [62] [63] [64] [65] . Furthermore, during an inflammatory response, HDL may undergo profound modifications both in mass and composition. Although it is difficult to establish whether changes in plasma lipoproteins simply reflect the severity of disease or can directly modify the host response to inflammation, low HDL-C levels inversely correlate with the severity of septic disease and associate with an exaggerated systemic inflammatory response [66] . Also in healthy subjects low HDL levels is associated with increased inflammatory response on endotoxin challenge compared to subjects with normal or high HDL levels [67] , without differences in the HDL proteome [68] .
By removing excess cholesterol from macrophages following the interaction with ABCA1 and ABCG1, apoA-I and HDL reduce the macrophage expression of pro-inflammatory mediators, including MCP-1 and CD11b and inhibits the proliferation of lymphocytes [69] . In addition, the removal of membrane cholesterol alter the composition of lipid rafts, membrane microdomains involved in several biological processes, and contribute to the tuning of the innate and the adaptive immune response, globally resulting in reduced inflammatory activity of macrophages and reduced lymphocyte activation [69] [70] [71] .
Beside a direct anti-inflammatory effect, HDL may counteract some of the pro-atherogenic effects of oxidized LDL (OxLDL); as example, HDL were shown to inhibit modified-LDL-induced monocyte-endothelium interaction [72] , to prevent OxLDL-induced inhibition of eNOS activation [73] , as well as OxLDL-induced platelet aggregation and adhesion [74] , endothelial cell death [75] and reactive oxygen species increase [76] . HDL prevent the effects of electronegative LDL naturally occurring in the plasma, whose concentration is increased in atherosclerosis-associated diseases, which exhibit a higher susceptibility to aggregation and may exert inflammatory effects [77] . HDL and apoA-I can also prevent the oxidation of LDL [78, 79] by binding and removing lipid hydroperoxides [80, 81] , as well as LDL aggregation by interacting with hydrophobic domains of the lipoprotein thus blocking the interactions that lead to aggregation [82] . Besides apoA-I, other HDL-associated apolipoproteins contribute to the anti-oxidant function, including apoE2 isoform [83] and apoA-IV [84] . HDL carry additional antioxidant enzymes able to prevent lipid oxidation or degrade lipid hydroperoxides, including PON1 and PAF-AH [85] .
HDL play a role also on endothelial function by stimulating the production of NO and prostacyclin (PGI2) in these cells [86] . The generation of NO occurs following the interaction of HDL with endothelial SR-BI [87] and subsequent activation of Akt, which in turn activates endothelial NO synthase (eNOS), which is localized in specialized membrane microdomains enriched in cholesterol named caveolae [88] . HDL also maintain the lipid environment in caveolae, thus promoting eNOS function [89] and the cyclooxygenase-2/PGI2 synthase coupling [90] . ApoA-I seems to play a relevant role in the vasodilatory effect of HDL [91] , but also S1P and PON1 contribute to the ability of HDL to stimulate NO production [92] [93] [94] . Both HDL2 and HDL3 (HDL2>HDL3) induce PGI2 secretion from endothelial cells; on the other hand, HDL2 inhibit the release of the potent vasoconstrictor thromboxane A2 (TXA2), while HDL3 induce its release [95] . The ratio PGI2/TXA2 suggests a more favorable vasodilatory effect for the HDL2 subfraction.
Endothelial apoptosis may result in an increased permeability of vascular endothelium; in addition, dysregulated apoptosis of atherosclerotic plaque cells may be an unfavorable process leading to plaque instability [96, 97] , and HDL may attenuate this process. In fact HDL inhibit macrophage [98] as well as endothelial cell apoptosis induced by different stimuli [59, 75, 99, 100] . ApoA-I and HDL-associated lysosphingolipids are the major components responsible for this effect [98, 99, 101] . HDL inhibits the apoptosis induced by several stimuli in endothelial cells [59, 99] , macrophages [102] and other cell types. Both proteins and lipids contribute to the antiapoptotic effect of HDL. ApoA-I is the major protein involved in this process [59] , but also HDL-associated lysosphingolipids [37, 101, 103, 104] and PON1 play a role as well [105] .
Small dense HDL3c have been shown to be most potent anti-apoptotic particles [59, 106] . On the other hand, plasma HDL-C levels positively correlates with the number of endothelial progenitor cells (which play a role in endothelial injury-repair process), evaluated as endothelial colony-forming units in culture [107] .
HDL possess also anti-thrombotic properties; in vitro, HDL inhibit platelet activity and the expression of endothelial tissue factor induced by thrombin [108, 109] ; furthermore, HDL stimulate the synthesis of prostacyclin, which inhibit platelet aggregation, by supplying arachidonic acid and inducing the expression of cyclooxygenase-2 [46, 90, 110] . In addition, HDL and apoA-I inhibit the self-association of von Willebrand factor, a process involved in the binding of platelet and formation of occlusive thrombi in small vessels [111] .
PATHOPHYSIOLOGICAL MECHANISMS OF DYSFUNCTIONAL HDL GENERATION

DEFECTIVE HDL REMODELLING
Several enzymes, proteins and receptors are involved in the metabolism and remodeling of HDL; mutations in the genes encoding for these proteins have been associated with changes in HDL-C plasma levels as well as in the composition and function of HDL particles [112] .
Under physiological conditions, LCAT plays a relevant role in HDL metabolism by mediating the esterification of free cholesterol (causing an increase in HDL size), which is then transferred from HDL to TG-rich lipoproteins by the action of CETP ( Figure 3 ). The activity of CETP leads to the reduction of HDL-C levels and HDL particle size. In this way, following the activity of LCAT, the newly formed pre-ß particles are converted into mature, spherical migrating HDL. The latter may be converted back to pre-ß-HDL by the action of CETP and other lipases: CETP mediates the transfer of CE between HDL and TG-rich lipoproteins, generating TG-rich HDL, which can be further hydrolyzed by hepatic lipase (HL) to small, TGrich HDL particles ( Figure 3 ). The joint action of CETP and HL promotes reduction in HDL size, formation of lipid-poor HDL particles, and shedding from HDL of lipid-free apoA-I, which can restart the lipidation cycle ( Figure 3 ). Another critical enzyme in the metabolism of HDL is endothelial lipase (EL), synthesized and secreted by endothelial cells and involved in the hydrolysis of HDL phospholipids. Its activity results in the destabilization of HDL particle, shedding of poorly lipidated apoA-I and hepatic uptake of the remodeled HDL particle [113] ( Figure 3 ). Thus, this enzyme serves as a negative regulator of plasma HDL-C levels, although its role in atherosclerosis is still unclear. While in vitro EL-mediated generation of lipid-poor apoA-I increased cholesterol efflux capacity, in vivo EL overexpression reduced HDL without apoA-I generation and with impaired serum cholesterol efflux capacity [114] .
When the activity of one of these proteins involved in HDL metabolism is altered, the process of maturation and remodeling of HDL is affected, leading to the formation of "dysfunctional" lipoproteins. The deficiency of LCAT-mediated esterification of free cholesterol leads to defective HDL maturation, characterized by the accumulation of pre-ß-particles [115] ( Figure 4 ). Reduced LCAT activity may be due to either mutations in the gene encoding for this protein or to pathological conditions, such as metabolic syndrome, type 2 diabetes or chronic kidney disease [116] [117] [118] . Genetic variants of LCAT reducing the activity of this protein are associated with reduced HDL-C plasma levels and alterations in HDL structure and particle distribution, with a selective depletion of large -particles and accumulation of small preβ-HDL which also contain apoA-II [119] . These alterations in HDL particle distribution translated into an improved ability of serum from LCAT deficient patients to efflux cholesterol through the ABCA1 transporter [120] . A similar pattern was observed in patients with metabolic syndrome, who exhibited a slightly reduced LCAT mass, increased pre-ß HDL and increased ABCA1mediated cholesterol efflux [116] . This was accompanied by reduction of HDL particle size and number and triglyceride enrichment [116] . In spite of this effect, the impact of LCAT deficiency on atherosclerosis is debated with either increased or decreased intima-media thickness (IMT) reported [120, 121] .
The activity of CETP, which remodels HDL particles and increases LDL-C and VLDL-C levels ( Figure 5 ), is increased in some conditions, such as hyperlipidemia. Genetic studies and a Mendelian randomization analysis have suggested a reduced cardiovascular risk in subjects carrying polymorphisms associated with reduced CETP activity [15, [122] [123] [124] . Subjects with mutations leading to CETP deficiency exhibit, in fact, increased levels of HDL-C, lower levels of LDL-C and a reduced incidence of CHD [125] . In particular, CETP-deficient subjects had increased levels of large HDL2 particles associated with a higher SR-BI/ABCG1-mediated cholesterol efflux capacity compared with control subjects [126, 127] . In addition, HDL isolated from CETP-deficient subjects exhibit normal anti-inflammatory and anti-oxidant properties [128, 129] , although they are less effective in inducing NO production, probably due to a reduced S1P content [128] , or to a reduced ability to interact with SR-BI [130] . The hypothesis that pharmacological inhibition of CETP might mimic the CETP-deficient phenotype, resulting in an overall improved HDL function and reduced cardiovascular risk, has been challenged by the results of clinical trials, which failed to show a cardiovascular benefit despite significant HDL-C level increase [12, 13, 131 ]. An exception is represented by anacetrapib that reduced the incidence of major coronary events compared with placebo in atorvastatin-treated patients with atherosclerotic vascular disease [14] . However, as anacetrapib also significantly reduced LDL-C levels, it is likely that the observed cardiovascular benefit depends on this effect [132] .
A post-hoc analysis of 2 large prospective study, however, suggested that very large HDL particles, which are formed upon CETP inhibition, are associated with higher risk of cardiovascular events despite apoA-I remains negatively associated to CAD risk [29] . Recently it has been shown that, in CETP transgenic mice, cholesterol efflux as well as PON1 activity were significantly increased and reactive oxygen species decreased by evacetrapib, while anacetrapib had no effect, despite similar effects on lipids [133] . As a result, anacetrapib worsened endothelium-dependent acetylcoline-induced vasorelaxation while evacetrapib had no effect [133] . Furthermore, the ACCENTUATE study with evacetrapib [134] showed that, although the treatment increased cholesterol efflux capacity, it also generated HDL particles with increased apoC-III content. ApoC-III-enriched HDL are less functional [135, 136] and might perhaps provide apoC-III to the arterial wall, which may trigger an inflammatory process in endothelial cells, characterized by increased expression of pro-inflammatory cytokines and increased adhesion of monocytes, as well as alterations of endothelial apoptosis [135, [137] [138] [139] . These findings suggest that, although effective in improving the overall lipid profile, pharmacological CETP inhibition might not associate to a vascular protective effect.
MYELOPEROXIDASE-INDUCED MODIFICATION OF HDL
One major pathway responsible for the generation of dysfunctional HDL involves myeloperoxidase (MPO), a heme protein overexpressed in human atherosclerotic lesions where it colocalizes also with macrophages [140] . Locally this enzyme produces hypoclorous acid (HOCl) and peroxynitrite (ONOO -) which convert free and protein-bound tyrosine residues to 3-chlorotyrosine and 3-nitrotyrosine [140] . An increased expression of MPO has been observed during the progression of atherosclerotic lesion into atherosclerotic plaque, with a maximal expression immediately before plaque rupture [141, 142] , which may suggest this enzyme as a marker of unstable advanced plaque. Accordingly, MPO was detected within atherosclerotic plaques of patients with acute coronary syndrome, in which was shown to form complexes with apoA-I [143] . Circulating HDL isolated from patients with cardiovascular disease, acute coronary syndrome or diabetes present high levels of both 3-chlorotyrosine and 3-nitrotyrosine [144] [145] [146] [147] . Chlorinated and nitrated adducts have been detected in human atherosclerotic lesions where they co-localize with macrophages [144, 145, 148] . In vitro MPO chlorinates and nitrates tyrosine 192 residue of apoA-I [149, 150] , a modification detected also in HDL isolated from human atherosclerotic tissues or diabetic subjects [146, 151] . The oxidation of this specific tyrosine residue results in an impaired ability of HDL to promote ABCA1-mediated cholesterol [144, 146, 150] . In vivo, the injection of MPO-oxidized apoA-I resulted in a significantly lower RCT compared to mice injected with native HDL [152] . Atherosclerotic plaques from mice injected with MPO-oxidized apoA-I were not different in size, but presented increased macrophage and lipid accumulation and reduced collagen content [152] . The latter observation is in line with the ability of chlorinated and nitrated HDL to inhibit SMC migration and exhibit a reduced ability to stimulate SMC proliferation, without significant effects on SMC apoptosis [153] . Furthermore, in experimental models of carotid stenosis, the injection of chlorinated or nitrated HDL resulted in increased neointima/media ratio and reduced SMC positive staining cells in the fibrous cap compared to native HDL-treated mice, thus suggesting that MPO-HDL might increase the vulnerability index of the plaque [153] .
In humans, serum MPO/HDL particle ratio was directly associated to incident cardiovascular disease (CVD) in a population-based cohort free from CVD at baseline [154] . The observation that MPO/HDL particle ratio was directly associated with high-sensitivity C-reactive protein and IL-18, and inversely associated with PON1 arylesterase activity [155] further linked MPO-HDL with increased vascular inflammation.
HDL GLYCATION
An increased generation of advanced glycation end products in a hallmark of diabetes. Nonenzymatic glycation may occur under conditions of chronic hyperglycemia (poorly controlled diabetes), leading to alterations of HDL composition (lipids, apoproteins and enzymes) and functionality [156] . In vitro, the exposure of endothelial cells to glycated HDL induces apoptosis by triggering mitochondrial dysfunction [157] and increases oxidative stress [158] .
In addition, glycated HDL are less effective in counteracting the inhibitory effect of OxLDL on endothelium-dependent vasorelaxation [159] and trigger vascular smooth muscle cell proliferation and migration [160] . The glycation of apoA-I alters the conformation of the apoprotein in regions that are critical for LCAT activation [161] , reduces its ability to promote cholesterol efflux from macrophages and to inhibit the expression of adhesion molecules and ROS formation [62, 162] . In humans, apoA-I glycation is associated with the severity of CAD and coronary artery plaque progression in patients with type 2 diabetes [163, 164] and with a significantly reduced apoA-I half-life [165] . Furthermore, HDL isolated from type 2 diabetic patients exhibited a reduced ability to catabolize membrane lipid hydroperoxides [166] , to reverse the OxLDL-induced inhibition of vasodilation [167] and overall a reduced antiinflammatory activity [168] .
Altogether these observations suggest that modification of HDL in diabetes may significantly impair their athero-protective functions and may contribute to the increased cardiovascular risk.
HDL ALTERATIONS DURING INFECTION/INFLAMMATION
Lipid metabolism and lipoprotein composition are altered during infection, and the reduction of plasma HDL-C levels is associated with changes in HDL composition and size. ApoA-I and phospholipids are reduced while serum amyloid A (SAA) and secretory phospholipase A2 (sPLA2) are increased in acute phase HDL [71, 169] . These changes appear to be associated with a protection toward infections and together with other immunomodulatory activities support the evolutionary conserved function of HDL in the immune response [70, 170] .
Following infection, total HDL particle number does not change, while a significant decrease in the number of small and medium size particles is observed [171] . SAA rapidly associates to HDL and promotes the displacement of apoA-I; thus becoming the main protein of acute-phase HDL [172, 173] while when the inflammatory triggers are removed, SAA is cleared rapidly over ∼72 h, [174] and is slowly replaced by apoA-I during recovery [175] . In parallel, during infection, the content of other HDL associated proteins (PON1, PAF-AH) is decreased, while ceruloplasmin content increases, with a net effect of reduced anti-oxidant capacity [176, 177] and increased content of pro-atherogenic lipids [178, 179] (Table 1) . Changes in HDL remodeling enzymes including the increase of endothelial lipase [180] and secretory phospholipase A2 [171] and the decrease of CETP and LCAT [66, 171] contribute to alter HDL lipid composition and is paralleled by the reduction of functionality [171, 181, 182] , including the ability to promote reverse cholesterol transport (Table 1 ) [183] .
These observations indicate a role of HDL in the protection against sepsis and suggest the possibility that SAA-HDL could be a marker of an efficient immune response. Nevertheless a SAA-ApoA-I crosslink was observed in acute phase HDL which was proposed to contribute to the amyloidogenic potential of these proteins [184] , further studies are needed to clarify this issue.
In summary, acute infections represent a conditions where HDL are rapidly and largely rearranged and represent a disease condition where pharmacological approaches aimed at improving HDL composition rather than HDL-C levels might play a role. Alterations in the function/composition of HDL particles may also result in the impairment of immune functions.
Vice versa patients with autoimmune diseases (such as systemic lupus erythematosus or
rheumatoid arthritis), which are at increased cardiovascular risk [185] , present altered HDL functionality, including reduced cholesterol efflux capacity, reduced antioxidant properties, and increased pro-inflammatory index [186] [187] [188] [189] [190] [191] [192] (Table 1) .
ALTERATIONS OF ATHEROPROTECTIVE PROPERTIES OF HDL IN CARDIOVASCULAR
DISEASE
Impaired cholesterol efflux capacity of HDL has been related to structural changes of HDL components; in particular, alterations of apoA-I, primarily due to oxidative modifications, account for this effect owing to a reduced ability of oxidized apoA-I to induce ABCA1-mediated cholesterol efflux in vitro [144, 150, [193] [194] [195] . Thus, HDL isolated from patients with cardiovascular disease have been shown to exhibit a reduced cholesterol efflux potential. This was observed with HDL isolated from patients with acute coronary syndrome or CAD patients compared with healthy subjects, despite similar levels of plasma HDL-C, which suggests an altered functionality of HDL (Table 1 ) [196] . Large HDL2 particles isolated from patients with familial hypercholesterolemia (FH) have a reduced capacity to mediate free cholesterol efflux via both SR-BI-and ABCG1-dependent pathways [197] . It has also been shown a reduction of plasma pre-ß1 HDL, the major acceptor of free cholesterol from cells, in a large cohort of patients with type 2 diabetes, which associates with reduced ABCA1-mediated cholesterol efflux (Table 1 ) [198] . Other HDL alterations have been associated to a reduced functionality.
For example, patients with established CAD have HDL3 particles enriched in specific proteins involved in lipid metabolism, complement activation and inflammatory response, such as apoE, apoC-IV, apoA-IV and complement C3 (a major effector of the complement system); the higher levels of apoE found in HDL3 particles suggests a redistribution of apoE from HDL2 to HDL3 with a consequent impairment of the cholesterol efflux capacity in patients with CAD [199] .
Other modifications of HDL3 in patients with cardiovascular disease may account for the reduced anti-oxidative activity, including a reduced content of PON1 and PAF-AH [177, 200] and a reduced phosphatidylcholine/sphingomyelin ratio, which may reflect increased surface rigidity [201] (Table 1) .
. HDL modified in vitro as well as HDL isolated from patients with CAD, diabetes, metabolic syndrome, chronic kidney disease or acute coronary syndrome fail to stimulate endothelial eNOS-activating pathways and NO production [94, [202] [203] [204] (Table 1) .
HDL isolated from patients with stable CAD or acute coronary syndrome (ACS) lose their ability to inhibit endothelial cell apoptosis and instead activate pro-apoptotic pathways [135] ( Table 1 ). The proteomic analysis of HDL showed a reduction in clusterin and increase in apoC-III content [135] (Table 1) ; in agreement cholesterol levels in apoC-III-containing HDL particles is positively associated with incident coronary heart disease [205] . In addition, HDL3 isolated from subjects with the metabolic syndrome exhibit reduced anti-apoptotic properties associated to altered physicochemical properties, including core CE depletion and TG enrichment [206] .
CLINICAL RELEVANCE OF DYSFUNCTIONAL HDL
Under pathological conditions, HDL can become dysfunctional, independently of their plasma levels, due to compositional and functional changes of lipoprotein, as reported in Table 1 . For example in patients with CAD, diabetes mellitus or chronic renal disease, HDL function is impaired [207] [208] [209] , as they exhibit significantly reduced protective functions, and rather acquire pro-atherogenic features [42, [210] [211] [212] [213] . Consistently, HDL cholesterol efflux capacity is strongly and inversely associated with both subclinical atherosclerosis and obstructive coronary disease even when adjusted for HDL-C and apoA-I levels [23] .
Patients with acute coronary syndrome as well as with stable CAD exhibit a reduced HDLmediated cellular cholesterol efflux compared with healthy subjects, even when matched by HDL-C levels; interestingly, it was reported that the reduction in HDL-mediated cholesterol efflux capacity remains impaired also three months later the ACS [196] . ACS is characterized by a high degree of inflammation, which results in elevated levels of acute phase proteins such as CRP and SAA; thus it is plausible that, during ACS, HDL particles may shift to a proinflammatory profile. In fact, levels of apoA-IV were significantly decreased, while SAA and complement C3 were increased in HDL particles of patients with ACS [213] , which may alter the functions of HDL. Alterations of the HDL proteome has been reported also in subjects with CAD [199, 214] . HDL2 isolated from patients with CAD, whose levels are reduced in patients with CAD, also have a higher content of apoC-III (an inhibitor of lipoprotein lipase) and contain less apoC-I (which inhibits CETP), which may alter the physiological remodeling of HDL particles and lead to the generation of dysfunctional HDL [214, 215] .
Patients with FH are characterized by a large elevation of LDL-C, but other lipid abnormalities are present as well. As example, beside the overall lower levels of plasma HDL-C, also qualitative alterations in this class of lipoproteins has been reported, including the enrichment in TG and sphingomyelin, a reduced ability to remove cholesterol from cells, as well as reduced anti-inflammatory and anti-oxidant capacities [216] . HDL2 and HDL3 levels are reduced compared with control subjects, and large HDL2 particles are less effective in promoting cholesterol efflux, probably due to modifications in their phospholipid content [197] .
An inverse relationship between HDL efflux capacity and development of atherosclerosis in FH patients has been observed; specifically, significant inverse relationships between SR-BIdependent HDL2 efflux capacity and carotid intima-media thickness and between ABCG1dependent HDL2 efflux capacity and carotid intima-media thickness have been observed [197] .
Of note, TG-enriched HDL3 isolated from FH patients showed a reduced capacity to inhibit the release of IL-8 from TNF-α-stimulated endothelial cells, but also the increased content in sphingomyelin and saturated fatty acid may contribute to the reduced anti-inflammatory activity of HDL3 [201, 217] . Whether these alterations modulate the clinical phenotype of FH remains to be investigated.
A reduced arylesterase activity, catalyzed by HDL-associated PON1, is associated with a high systemic oxidative stress; it was shown that in patients with chronic heart failure (HF), impaired antioxidant function of HDL (measured as PON1 activity) was associated with adverse cardiac events and HF-related hospitalizations [218] as well as with a higher risk of incident long-term adverse cardiac events, independent of established clinical and biochemical risk factors [219] . In addition, impaired antioxidant function of HDL has been associated with premature acute myocardial infarction [220] . The impaired antioxidant activity of HDL was observed during the acute phase of acute myocardial infarction (AMI), but also persisted during the stable phase of the disease 1 year after the event [220] . The analysis of HDL particle size distribution indicated a reduced number of large HDL particles in patients with premature AMI [220] . Furthermore, the correlation of large and intermediate HDL particles with antioxidant function observed in control patients was lost in patients with premature AMI, which may suggest that the reduction of very large particles and the impaired function of large and medium particles might contribute to the pathogenesis of premature acute myocardial infarction, thus helping to explain the lost of the inverse relationship between HDL-C levels and CV risk in patients with CAD [16] .
Subjects with type 2 diabetes mellitus (T2DM) have a greater risk of developing cardiovascular disease ; this disease is characterized by the presence of the "atherogenic dyslipidaemias", that includes high TG levels, high levels of small dense pro-atherogenic LDL and low HDL-C levels [221] . Beside the reduced HDL-C levels, HDL particles from diabetic patients are dysfunctional, due to both the presence of advanced glycation end products, and to the increased oxidative stress and inflammation that lead to HDL modification and may reduce their ability to promote cholesterol efflux [156] or their anti-inflammatory capacity [62] . In addition, HDL from type 2 diabetic patients with poor glycaemic control have lower antioxidant and anti-inflammatory activities compared with those from patients with good glycaemic control [222] .
Chronic kidney disease is a pathological conditions in which the progressive loss of kidney function leads to the worsening of the characteristic dyslipidemic profile, with low plasma levels of HDL-C [223] ; beside, several other alterations are present in these patients, including abnormalities of HDL metabolism, LCAT deficiency, modification of apoA-I, TG enrichment, defective cholesterol transport and impaired anti-inflammatory activity [224] . In CKD patients, HDL are not able to provide NO to the endothelium to a relevant extent, a mechanism dependent on the activation of toll-like receptor 2 [225] .
As reported for CAD subjects, the inverse association between HDL-C levels and CVD risk is significantly attenuated as the glomerular filtration rate (a measure of renal function) decreases [209, 226] . The changes in HDL subfractions and their oxidized subfraction particles are related to the severity of the disease, and higher amount of oxidized HDL may contribute to the increased CV risk in patients with advanced CKD [227, 228] . HDL from patients with end-stage renal disease on dialysis have a dramatically reduced cholesterol efflux capacity compared with matched subjects with normal kidney function, and statin therapy did not improve HDL efflux capacity [229] . The HDL anti-inflammatory activity was reduced, but in the subgroup of patients on statin therapy it was similar to that of control subjects taking statins [229] . The presence of dysfunctional HDL significantly associates with an overall worse condition, including significantly higher co-morbidities and a lower quality of life, in hemodialysis patients, as suggested by the observation that patients with a higher HDL proinflammatory index have a higher hazard ratio for death than those whose HDL maintain their anti-inflammatory properties [230] .
Conclusions
Atherosclerosis and related diseases, as well as other pathological conditions including acute phase reactions and immune diseases, are associated with significant alterations in both HDL-C levels and HDL particle structure/composition. Although HDL-C levels inversely correlate with the risk of cardiovascular disease, the observation that such relationship is mitigated in patients with established cardiovascular disease, together with the findings that very high levels of HDL-C do not associate with cardiovascular benefit and even increased the risk of CAD, and that pharmacological inhibition of CETP does not translate into a cardiovascular benefit despite significant increase in HDL-C levels, limit the relevance of HDL-C levels as an index of atheroprotection but rather point toward the investigation of HDL function in atherosclerosis . In line with this hypothesis, clinical evidence suggests that high levels of HDL-C not always are atheroprotective, and instead may mark pro-inflammatory/pro-atherogenic features. On the other hand, small peptides that mimic the function of apoA-I render HDL less inflammatory [27] , promote macrophage reverse cholesterol transport [231] and inhibit LDL aggregation [232] , and were found to be effective in several animal models of disease [233] [234] [235] [236] [237] . These observations also reveal the limitations of measurements based only on the determination of HDL-C levels. A recent analysis of the JUPITER trial showed that, in patients in which the weight of the main cardiovascular risk factor, LDL-C, is significantly attenuated by the treatment with a statin, it is possible to highlight the clinical relevance of HDL functionality [238] . These results also suggested that pharmacological approaches aimed at increasing HDL-C plasma levels may not automatically translate into a clinical benefit and instead treatments that control hypercholesterolemia/inflammation may also result in an improvement of HDL functionality. 
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